Guardant Health, Inc.
GH
Rangering i aksjer
#1081
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Aksjekurs
$161.19
Markedsverdi
$21.63B
Endring (1 dag)
2.10%
Endring (1 år)
129.62%
Land
US
Handel Guardant Health, Inc. (GH)
Kategori
Healthcare
P/E-forhold for Guardant Health, Inc. (GH)
P/E-forhold per October 2026 TTM: -46.70
Ifølge Guardant Health, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -46.70. Ved slutten av 2023 hadde selskapet en P/E på -6.32.
P/E-forholdshistorikk for Guardant Health, Inc. fra 2016 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | -46.70 | 443.68% |
| 2024 | -8.59 | 36.01% |
| 2023 | -6.32 | 48.81% |
| 2022 | -4.25 | -83.00% |
| 2021 | -24.98 | -49.55% |
| 2020 | -49.52 | -47.09% |
| 2019 | -93.58 | 149.04% |
| 2018 | -37.58 | 37.33% |
| 2017 | -27.36 | 196.49% |
| 2016 | -9.23 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 36.15 | -177.42% |
US
|
|
| 39.77 | -185.16% |
US
|
|
| -290.26 | 521.51% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -173.20% |
US
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.